Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,613 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.
Ogawa K, Hosokawa A, Ueda A, Saito S, Mihara H, Ando T, Kajiura S, Terada M, Tsukioka Y, Horikawa N, Kobayashi T, Note M, Sawasaki K, Fukuoka J, Sugiyama T. Ogawa K, et al. Gastroenterol Res Pract. 2012;2012:640401. doi: 10.1155/2012/640401. Epub 2012 Feb 15. Gastroenterol Res Pract. 2012. PMID: 22474446 Free PMC article.
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Ueda A, Hosokawa A, Ogawa K, Yoshita H, Mihara H, Ando T, Kajiura S, Fujinami H, Nishikawa J, Minemura M, Terada M, Kobayashi T, Horikawa N, Yabushita K, Note M, Sugiyama T. Ueda A, et al. Among authors: ogawa k. Anticancer Res. 2013 Nov;33(11):5107-11. Anticancer Res. 2013. PMID: 24222156
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T. Kajiura S, et al. Among authors: ogawa k. Am J Clin Oncol. 2016 Feb;39(1):13-7. doi: 10.1097/COC.0000000000000018. Am J Clin Oncol. 2016. PMID: 24322336 Clinical Trial.
Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T, Ueda A, Ogawa K, Motoo I, Kajiura S, Nakajima T, Hirano K, Okumura T, Tsukada K, Hara T, Suzuki N, Nakada N, Horikawa N, Fujii T, Yasuda I. Ando T, et al. Among authors: ogawa k. In Vivo. 2021 Jan-Feb;35(1):475-482. doi: 10.21873/invivo.12281. In Vivo. 2021. PMID: 33402499 Free PMC article.
Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer.
Ando T, Hosokawa A, Sakumura M, Motoo I, Kajiura S, Hirano K, Miwa T, Yokota T, Nakada N, Ueda Y, Ueda A, Tsukada K, Ogawa K, Nakaya A, Teramoto A, Nanjo S, Mihara H, Fujinami H, Fujii T, Yasuda I. Ando T, et al. Among authors: ogawa k. Oncology. 2023;101(1):59-68. doi: 10.1159/000526577. Epub 2022 Sep 14. Oncology. 2023. PMID: 36103845
5,613 results